Shots: Lupus Therapeutics (subsidiary of Lupus Research Alliance) collaborates with Takeda to evaluate TAK-079 (NCT03724916) in P-I clinical study assessing TAK-079 vs PBO in 24 patients with moderate to severe […]readmore
Tags : Agreement
Shots: Novartis & Target PharmaSolutions collaborates for the onset of global TARGET-DERM study evaluating adult and pediatric patients with immune-mediated inflammatory skin conditions (IMISCs) The initial focus of the collaboration […]readmore
Shots: TetraGenetics to receive $25M upfront, $248M milestones as contingent payments, FTE payments and royalties upto 7% on sales of product. Imbrium to get license for TetraGenetics’ TetraExpress Technology with […]readmore
Shots: Voyager to receive $65M upfront and will be responsible for research, IND submission and onset of P-I trial for targets provided by AbbVie. AbbVie to get a WW option […]readmore
Shots: Eurofarma to get exclusive license rights to develop and commercialize NLS-1 Pharma’s Nalazol Therapy in Central & South America and to take care of its regulatory approval In 2002, […]readmore
Shots: Morphic to receive upfront, $725M milestones, and royalties on WW sales of products. Janssen to get exclusive option to license integrin therapies post IND submission and will fund the […]readmore
Shots: The companies entered into an agreement to assess insulin dose data from Novo Nordisk’ pre-filled insulin pen connected to the digital health tool marked with Abbott’s FreeStyle Libre system […]readmore
Shots: The companies enter into an agreement to jointly evaluate safety & efficacy of Alkermes’ ALKS 4230 in combination with Clovis Oncology’s Rucaparib & Lucitanib with equal cost sharing in […]readmore
Shots: AbCellera to receive technology access fee, funding, milestones, and royalties on sales of products. Novartis to get rights to license AbCellera’s technology for its 10 unknown targets Additionally, AbCellera […]readmore
Shots: Codexis to receive $3M milestone and NHSc to get exclusive WW rights to develop and commercialize Codexis’s CDX-6114 for phenylketonuria (PKU) In 2017, Codexis & NHSc collaborated to develop […]readmore